头孢地尔作为ICU碳青霉烯耐药革兰阴性菌感染的挽救治疗
Ten critically ill patients with either bacteremia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, or New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae received cefiderocol.…
要点
- 头孢地尔对碳青霉烯耐药鲍曼不动杆菌等革兰阴性菌有体外活性
- 2例出现微生物学失败,需前瞻性研究进一步评估
主要发现
- 所有菌株最低抑菌浓度≤2 μg/mL。
关键数值与推荐
- 所有菌株对头孢地尔的最低抑菌浓度≤2 μg/mL。
临床怎么用
- 对于ICU中由碳青霉烯耐药鲍曼不动杆菌、嗜麦芽窄食单胞菌或产NDM型金属β-内酰胺酶肺炎克雷伯菌引起的血流感染或呼吸机相关性肺炎,头孢地尔可作为挽救治疗选择。
局限性
- 本文为病例系列,样本量小,需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ten critically ill patients with either bacteremia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, or New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae received cefiderocol. All strains had minimum inhibitory concentration ≤2 μg/mL. Thirty-day clinical success and survival rates were 70% and 90%, respectively. Two patients had a microbiological failure. Future prospective studies are warranted.
引用
- Falcone M, Tiseo G, Nicastro M, et al. Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients. Clin Infect Dis. 2021. PMID: 32941593. doi:10.1093/cid/ciaa1410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。